Atara Biotherapeutics Expands ATM Offering to $79.2M, Reversing Prior Limit
ATRA has more than doubled off its 52-week low of $3.92.
Summary
Atara Biotherapeutics has expanded its ATM offering to $79.2 million, reversing a prior $11.1 million limit, providing a critical capital lifeline but also signaling massive potential dilution for shareholders.
Key Events · Financing and Capital Events · ATRA
-
ATM Program Expansion
The company can now offer and sell up to $79,269,007 in common stock through its At-The-Market (ATM) program.
-
Reversal of Prior Limit
This action reverses a previous restriction from March 16, 2026, which had limited the ATM offering to $11.1 million due to public float requirements.
-
Significant Potential Dilution
The remaining $79.2 million available for sale represents nearly 95% of the company's current market capitalization, indicating substantial potential dilution for existing shareholders.
-
Critical Capital Access
The expanded capital access is vital for the company, which recently disclosed a going concern warning and received a Nasdaq delisting notice, providing a potential lifeline for its operations.
Analysis · ATRA · Life Sciences
This filing significantly increases Atara Biotherapeutics' ability to raise capital through its At-The-Market (ATM) program, allowing it to sell up to an additional $79.2 million in common stock. This reverses a previous restriction from March 16, 2026, which had limited the ATM to $11.1 million due to public float requirements. The expanded access to capital is critical for the company, which recently issued a going concern warning and received a Nasdaq delisting notice. While providing a potential lifeline for survival, this represents substantial potential dilution for existing shareholders, equivalent to nearly 95% of the current market capitalization.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATRA was trading at $9.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.5M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.